Quest Diagnostics (NYSE: DGX) is expected to report Q2 earnings on July 19. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Quest Diagnostics' revenue will improve 2.0% and EPS will improve 4.5%.

The average estimate for revenue is $1.94 billion. On the bottom line, the average EPS estimate is $1.17.

Revenue details
Last quarter, Quest Diagnostics notched revenue of $1.94 billion. GAAP reported sales were 6.3% higher than the prior-year quarter's $1.82 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $1.07. GAAP EPS were $0.99 for Q1 compared to -$0.33 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 42.5%, 220 basis points better than the prior-year quarter. Operating margin was 16.5%, 100 basis points better than the prior-year quarter. Net margin was 8.2%, 1,120 basis points better than the prior-year quarter.

Looking ahead
The full year's average estimate for revenue is $7.71 billion. The average EPS estimate is $4.59.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 547 members out of 580 rating the stock outperform, and 33 members rating it underperform. Among 181 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 174 give Quest Diagnostics a green thumbs-up, and seven give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Quest Diagnostics is hold, with an average price target of $61.53.